



Immunomodulatory Effects of Adenoviral CTLA4-EGFP Transfected Dendritic Cells in Allotransplantation.

Ashley Newland

Transplantation Immunology Laboratory
The Queen Elizabeth Hospital

Date of Submission: January 2006

This thesis is submitted in fulfilment of the requirements of the award of PhD in Medicine at The University of Adelaide.

Table of Contents

List of Figures	VIII
Publications	X
Presentations	XI
Declaration	XII
Acknowledgements	XIII
Abbreviations	XIV
Summary	XVII

Chapter 1: Review of Literature

1.1. Introduction	2
1.2. T Cell Activation	2
1.3. The Immunological Synapse	3
1.4. The CD28 Costimulatory Pathway	4
1.4.1. CD28 Expression and Function	4
1.4.2. CD28 Biochemical Pathways	5
1.5. CTLA4 Expression, Structure and Function	6
1.5.1 Regulation of CTLA4 expression and distribution	6
1.5.2. The Molecular Structure of CTLA4	8
1.5.3. Functional Characteristics of CTLA4	9
1.5.3.1. The “Proximal Competition” Model of CTLA4 Induced Antagonism	10
1.5.3.2. The “Distal Signaling” Model of CTLA4 Induced Antagonism	11
1.5.3.3. The “Threshold” Model of CTLA4 Induced Antagonism	11
1.5.3.4. The “Attenuation” Model of CTLA4 Induced Antagonism	12
1.5.4. CTLA4 Signaling Pathways	12
1.6. Expression of CD80 and CD86 Ligands	13
1.6.1. CD80 and CD86 Expression	13
1.6.2. CD80 and CD86 Binding to CD28 and CTLA4	14
1.7. Other Regulators of CD28 Costimulation	16
1.8. Interleukin 10 (IL10) Expression, Structure and Function	17
1.8.1. Interleukin 10 Expression	17
1.8.2. The Molecular Structure of IL10	18
1.8.3. The Interleukin 10 Receptor (IL10R)	18
1.8.4. The Functional Characteristics of IL10	19
1.8.5. Viral IL10	20
1.8.6. IL10 Signaling Pathways	21
1.9. Immunology of Transplant Rejection	22
1.9.1. Direct and Indirect Pathways of Allorecognition	22
1.9.2. The Involvement of the Th1/Th2 Paradigm in Transplantation	22
1.10. Mechanisms of Alloreactive T Cell Hyporesponsiveness	24
1.10.1. Anergy	24
1.10.2. Apoptosis and Activation Induced Cell Death (AICD)	25
1.10.3. Generation of and interactions with regulatory T cells	25

1.11. Current Immunosuppressive Treatments to Prevent Transplant Rejection	26
1.12. Inhibition/Blockade of the CD28 Costimulatory Pathway in Transplantation	29
1.12.1. Generation of Soluble CTLA4-Ig Fusion Proteins	29
1.12.2. Blockade of the CD28 Costimulatory Pathway	29
1.12.3. The Effects of CTLA4-Ig on Th1/Th2 Pathways in Allograft Transplantation	31
1.12.4. IL10 and Transplantation	31
1.12.5. Limitations of Systemic CTLA4-Ig and IL10 Treatments	32
1.13. Dendritic Cells as Gene Therapy Targets to Induce Transplantation Tolerance	33
1.13.1. The Role of Dendritic Cells in Transplantation	33
1.13.2. Genetic Modification of Dendritic Cells	34
1.13.3. Genetically Engineered Dendritic Cells in Tolerance Induction	37
1.14. Targeting Multiple Dendritic Cell Pathways in Allograft Transplantation	38
1.15. The Ovine Model of Renal Transplantation	40
1.16. Project Aims	42
Chapter 2: General Materials and Methods	
2.1. Materials	45
<i>2.1.1. Antibodies</i>	<i>45</i>
2.1.1.1. Anti-Human Antibodies	45
2.1.1.2. Anti-Ovine Antibodies	45
2.1.1.3. Control Antibodies	46
2.1.1.4. Secondary Antibodies	46
2.1.1.5. Other Antibodies	46
<i>2.1.2. Cell Lines</i>	<i>47</i>
2.1.2.1. Bacterial Cell Lines	47
2.1.2.2. Cell Culture Cell Lines	47
<i>2.1.3. Cytokines and Recombinant Proteins</i>	<i>47</i>
<i>2.1.4. Radiochemicals</i>	<i>48</i>
<i>2.1.5. Flow Cytometry Reagents</i>	<i>48</i>
<i>2.1.6. Tissue Culture Reagents</i>	<i>48</i>
<i>2.1.7. Histological Reagents</i>	<i>49</i>
<i>2.1.8. Molecular Biology Reagents</i>	<i>49</i>
<i>2.1.9. Plasmid Vectors</i>	<i>51</i>
<i>2.1.10. Immunoprecipitation Reagents</i>	<i>51</i>
<i>2.1.11. Other Reagents</i>	<i>52</i>
2.2. Solutions and Buffers	53
2.2.1. Agarose Gel Electrophoresis Buffers and Solutions	53
2.2.2. RNA Extraction Buffers and Solutions	53
2.2.3. Cloning and Transfection Buffers and Solutions	54
2.2.4. Tissue Culture Buffers and Solutions	56
2.2.5. Immunoprecipitation Buffers	57
2.2.6. Flow Cytometry Buffers and Solutions	60
2.2.7. Dephosphorylation Buffers and Solutions	60

2.2.8. ELISA Solutions	60
2.2.9. Immunohistology Solutions	61
2.3. General Methods	62
2.3.1. Cell Culture	62
2.3.1.1. Ovine and Human PBMC Extraction	62
2.3.1.2. Human Monocyte Derived Dendritic Cells	62
2.3.1.3. Nylon Wool Isolation of T Cells	63
2.3.1.4. Mixed Lymphocyte Reaction	63
2.3.1.5. Cell Lines	64
2.3.2. Molecular Biology Methods	64
2.3.2.1. Total RNA Extraction	64
2.3.2.2. Reverse Transcription (RT)	65
2.3.2.3. Polymerase Chain Reaction (PCR)	65
2.3.2.4. Agarose Gel Electrophoresis	66
2.3.2.5. Endonuclease Restriction Digestion of DNA	67
2.3.2.6. Agarose Gel Purification of Restriction Digest Products	67
2.3.2.7. Ultraclean™ Purification of DNA	68
2.3.2.8. Ligation of DNA Fragments into Cloning Vectors	68
2.3.2.9. Dephosphorylation of DNA Fragments	68
2.3.2.10. Preparation of Competent <i>E. Coli</i> TGF1 α and DH10 β Cells	69
2.3.2.11. Transformation of Competent <i>E. Coli</i> Cells	69
2.3.2.12. Plasmid Mini-preparation (Mini-prep)	70
2.3.2.13. Plasmid Midi-preparation (Midi-prep)	70
2.3.2.14. DNA Sequencing	71
2.3.2.15. Transfection of CHO cells with Purified Plasmids	71
2.3.3. Adenoviral Methods	72
2.3.3.1. Preparation of Electrocompetent BJ5183 Cells	72
2.3.3.2. Electrotransfection of BJ5183 Cells	72
2.3.3.3. Screening of Colonies for Homologous Recombination	73
2.3.3.4. Transformation of DH10 β <i>E. Coli</i> cells	73
2.3.3.5. Lipofectamine Transfection of Adenoviral Constucts into HEK-293 Cells	74
2.3.3.6. Preparation of Adenoviral HEK-293 Cell Lysates	74
2.3.3.7. Infection of HEK-293 Cells and Scale-up Viral Production	75
2.3.3.8. Caesium Chloride (CsCl) Density Gradient Purification of Adenoviral Particles	75
2.3.3.9. Dialysis of CsCl Purified Adenoviral Particles	76
2.3.3.10. Cytopathic Effect Assay (CPE) Quantitation of Adenoviral Titers	77
2.3.4. Flow Cytometry	77
2.3.4.1. Cell Surface Staining	77
2.3.4.2. FITC-Dextran Assay	78
2.3.5. Histochemistry	78
2.3.5.1. Biopsy Preparation	78
2.3.5.2. Hematoxylin and Eosin Staining	79
2.3.5.3. Immunohistochemistry	79
2.4. Centrifuges	80

Chapter 3: Immunomodulation of the Human DC-MLR by Combined IL10 and CTLA4-Ig Treatment

3.1. Introduction	82
3.2. Materials and Methods	84
3.2.1. Preparation of Cell Populations	84
3.2.2. Monoclonal Antibodies and Flow Cytometry	85
3.2.3. Proliferation Assays	85
3.2.4. Restimulation Assay	86
3.2.3. CFSE-MLR	86
3.3. Results	87
3.3.1. Phenotype of Human Monocyte-Derived DC and Associated Function	87
3.3.2. Immunomodulatory Properties of IL10 and CTLA4-Ig	87
3.3.3. Combined Treatment with IL10 and CTLA4-Ig in the DC-MLR Induces T Cell Hyporesponsiveness	89
3.3.4. CD4 ⁺ and CD8 ⁺ T cell Proliferation is Inhibited by IL10 and CTLA4-Ig in the CFSE-MLR	89
3.3.5. T Cells Stimulated by DC in the Presence of CTLA4-Ig in Combination with IL10 are Hyporesponsive to Restimulation	90
3.3.6. IL10 and CTLA4-Ig Mediated Inhibition of the DC-MLR is not Dependent on CD4 ⁺ CD25 ⁺ Regulatory T Cells	90
3.3.7. NK Cells are Required for the Inhibition of T Cell Proliferation by Sub-Optimal Doses of IL10 and CTLA4-Ig	91
3.3.8. NK Cells Influence DC Function	92
3.3.9. NK Cells Prime CD4 ⁺ T Cell Proliferation in a CTLA4-Ig Sensitive Manner	93
3.4. Discussion	94

Chapter 4: Isolation and Characterisation of Ovine DC Derived from Afferent Lymph

4.1. Introduction	103
4.1.1. Isolation of Ovine Dendritic Cells from Lymph Nodes Draining the Skin	103
4.1.2. <i>In vivo</i> Properties of Dendritic Cells	104
4.2. Materials and Methods	107
4.2.1. Cannulation	107
4.2.2. Metrizamide Purification of Ovine DC from Lymph	107
4.2.3. Flow Cytometry	108
4.2.4. Dendritic Cell Mixed Lymphocyte Reaction	108
4.2.5. PKH26 Labeling	109
4.2.6. Normal Lymphocyte Transfer Reaction	109
4.2.7. Immunohistological Analysis of Skin Biopsies	110
4.2.8. RNA Extraction from Skin Biopsies and PCR analysis of IL-2 mRNA Expression	110

4.2.9. Mitomycin C Treatment of PBMC	110
4.2.10. Sensitisation Assay	111
4.3 Results	112
4.3.1. Phenotype of Ovine Pseudo-Afferent Derived DC	112
4.3.2. Stimulatory Capacity of Ovine DC	112
4.3.3. Dendritic Cells Rapidly Migrate to the Draining Lymph Node	113
4.3.4. Intradermal Injection of Allogeneic DC and PBMC Elicits a Strong NLT Response	113
4.4. Discussion	115

Chapter 5: Generation of an Adenoviral Ovine CTLA4-EGFP Construct and the Immunomodulatory of Transduced DC

5.1. Introduction	120
5.2. Methods	124
5.2.1. Cloning of the Extracellular Domain of Ovine CTLA4	124
5.2.2. Generation of Adenoviral Constructs	124
5.2.3. Preparation of CTLA4-EGFP Fusion Proteins	125
5.2.4. Immunoprecipitation from Infected Fibroblasts	125
5.2.5. Quantification of EGFP and CTLA4-EGFP Fusion Proteins by ELISA	126
5.2.6. CTLA4-EGFP Binding Assay	127
5.2.7. Two-Way Mixed Lymphocyte Reaction	128
5.2.8. Genetically Modified DC as Stimulators in the MLR	128
5.3. Results	129
5.3.1. Generation and Characterisation of Fusion Protein Constructs	129
5.3.2. Generation and Characterisation of Adenoviral Constructs	129
5.3.3. Adenoviral Transfection of Ovine Fibroblasts	130
5.3.4. Secretion and Function of Ovine CTLA4-EGFP from Adenovirally Infected Fibroblasts	131
5.3.5. Binding of CTLA4-EGFP to Ovine and Human DC	131
5.3.6. Adenoviral CTLA4-EGFP Transfected DC have Reduced Allostimulatory Capacity	132
5.4. Discussion	134

Chapter 6: Immunomodulatory Function of Ovine DC Transfected with Adenoviral CTLA4-EGFP in a Reconstituted NOD-*scid* Model of Ovine Skin Rejection

6.1. Introduction	141
6.2. Methods	144
6.2.1. NOD- <i>scid</i> mice	144
6.2.2. Harvesting of Ovine Skin	144
6.2.3. Grafting of Ovine Skin	144
6.2.4. Intraperitoneal Challenge with Allogeneic Ovine PBMC and DC	145
6.2.5. Adenoviral Transfection of Ovine DC	146
6.2.6. ELISA Quantification of CTLA4-EGFP and EGFP	146

6.2.7. Histological Analysis of Skin Biopsies	146
6.2.8. Rejection Scores	147
6.3. Results	148
6.3.1. Ovine Skin Engraftment in NOD- <i>scid</i> Mice	148
6.3.2. Injection of Allogeneic DC and PBMC Provokes Rejection of Ovine Skin Allografts	148
6.3.3. Dendritic Cells Transfected with Adenoviral Vectors Migrate to the Skin Graft after Intraperitoneal Injection	149
6.3.4. Injection of Donor-Specific Ovine DC Transfected with Adenoviral CTLA4-EGFP Protects Ovine Skin Grafts from Rejection	149
6.4. Discussion	151
Chapter 7: Concluding Remarks	
7.1. Concluding Remarks and. Future Directions	157
Appendices	
Appendix 1. Primers	165
Appendix 2. Adenoviral Vectors	166
Appendix 3. Ovine CTLA4 Sequence from CTLA4-EGFP	167
Appendix 4. Ovine CTLA4-Ig Sequence	168
Appendix 5. Ovine IL10 Sequence from IL10-DsRED2	169
Reference List:	170

Summary

T cell activation occurs by the recognition of antigens presented by antigen presenting cells in the presence of sufficient CD28 costimulation. CTLA4 fusion proteins and interleukin 10 (IL10) are able to abrogate CD28 costimulation and therefore T cell activation. This thesis investigates the combined activity of these agents on allo-immunity and characterises the development of a gene therapy strategy utilising dendritic cells (DC) as a cellular vehicle to deliver CTLA4 fusion proteins.

Chapter 3 describes the effect of combined treatment of the DC-MLR with suboptimal doses of CTLA4-Ig and IL10. Inhibition of the MLR was augmented using the combination of the agents and interestingly a key role for Natural Killer (NK) cells in sensitising both DC and T cells to the inhibitory function of CTLA4-Ig and IL10 at low concentrations was highlighted.

Chapter 4 details the isolation and characterisation of ovine DC obtained by cannulation of the afferent lymphatics of the prefemoral lymph node of sheep. Importantly the isolated DC were potent allo-stimulators of the DC-MLR *in vitro* and were able to rapidly migrate to secondary lymphoid tissues upon *in vivo* administration. Moreover the intradermal injection of allogeneic DC and lymphocytes provoked a strong cutaneous reaction, confirming *in vivo* function and supporting the use of these cells for genetic manipulation to induce alloreactive T cell hyporesponsiveness.

Chapter 5 describes the generation of an adenoviral construct encoding a fusion of the extracellular domain of ovine CTLA4 and the gene for Enhanced Green Fluorescent Protein (EGFP). The adenoviral vector was able to infect both fibroblasts

and dendritic cells allowing production of CTLA4-EGFP proteins and detection of CTLA4-EGFP expression in transfected cells by virtue of the inherent fluorescence of EGFP. CTLA4-EGFP was able to bind to the CD80/86 ligands expressed on DC resulting in alloreactive T cell hyporesponsiveness. Moreover both ovine and human DC transfected with the adenoviral CTLA4-EGFP construct were able to inhibit the DC-MLR providing *in vitro* proof of concept and supporting the assessment of adenoviral CTLA4-EGFP transduced DC in an *in vivo* model of alloreactivity.

In **Chapter 6** an immunocompromised NOD-*scid* model of vascularised ovine skin transplantation was used to test the ability of adenoviral CTLA4-EGFP transduced DC to modify ovine skin allograft rejection after challenge with allogeneic ovine lymphocytes. Adenoviral CTLA4-EGFP transduced DC were able to migrate to the skin allograft and in comparison to DC transfected with the adenoviral vector blank control, inhibited rejection of the skin allograft. Moreover the inhibition of rejection was not associated with detectable levels of CTLA4-EGFP in circulation, indicating that adenoviral CTLA4-EGFP transduced DC are able to inhibit alloreactivity without the requirement of systemic immunosuppression. These data indicate that CTLA4-EGFP transduced DC are able to induce alloreactive T cell hyporesponsiveness *in vitro* and *in vivo* and supports further investigation in a preclinical ovine model of renal transplantation.